Skip to main content

Drug Interactions between chikungunya vaccine, live (cvx 317) and CNJ-016 Injection

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

vaccinia immune globulin chikungunya vaccine, live (cvx 317)

Applies to: CNJ-016 Injection (vaccinia immune globulin) and chikungunya vaccine, live (cvx 317)

Consumer information for this interaction is not currently available.

ADJUST DOSING INTERVAL: The passive transfer of antibodies present in immune globulin preparations may interfere with the immune response to live vaccines.

MANAGEMENT: Immunization with live vaccines should be deferred until approximately 6 months after administration of vaccinia immune globulin intravenous (VIGIV). If such vaccinations are given shortly before or after VIGIV therapy, a revaccination may be necessary. An additional dose of live measles, mumps, or rubella vaccine is usually not needed if the vaccine was administered at least two weeks prior to immune globulin administration.

References

  1. "Interference of immune globulin with measles and rubella immunization." Eur J Pediatr 152 (1993): 536
  2. CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer